MedTrace Logo

Study of Panitumumab in the Treatment of Carcinoid Syndrome

NCT01172717 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-07-26

No results posted yet for this study

Summary

The primary hypothesis of this study is that panitumumab, an inhibitor of the epidermal growth factor receptor (EGFR), is an effective treatment for carcinoid syndrome in people who fail or do not adequately respond to octreotide or other supportive therapies.

Conditions

  • Carcinoid Syndrome

Interventions

DRUG

Panitumumab

Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Boston Medical Center

    lead OTHER

Principal Investigators

  • Kevan Hartshorn, MD · Boston Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01172717 on ClinicalTrials.gov